MARKET

KALA

KALA

Kala Pharmaceuticals Inc
NASDAQ
0.4020
-0.0256
-5.99%
Opening 15:24 02/11 EST
OPEN
0.4180
PREV CLOSE
0.4276
HIGH
0.4223
LOW
0.3811
VOLUME
605.22K
TURNOVER
--
52 WEEK HIGH
20.60
52 WEEK LOW
0.3801
MARKET CAP
11.20M
P/E (TTM)
-0.0677
1D
5D
1M
3M
1Y
5Y
1D
Kala Bio files to sell 241.44M shares of common stock for holders
TipRanks · 1d ago
Kala Bio Inc. Files Initial Beneficial Ownership Statement for Director Hillel D. Posen
Reuters · 1d ago
Weekly Report: what happened at KALA last week (0202-0206)?
Weekly Report · 2d ago
Kala Bio CFO, CEO David Lazar Resigns, Avi Minkowitz Appointed Successor
Benzinga · 5d ago
Kala Bio Inc. Appoints Avi Minkowitz as CEO and CFO
Reuters · 5d ago
Kala Bio Inc. ernennt Avi Minkowitz zum CEO und CFO
Reuters · 5d ago
KALA BIO INC - AVI MINKOWITZ APPOINTED AS CEO AND CFO OF KALA BIO - SEC FILING
Reuters · 5d ago
KALA BIO expands preferred financing and shareholder authorizations
TipRanks · 02/02 11:32
More
About KALA
KALA BIO, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research, development, and commercialization of therapies for rare and severe diseases of the eye. The Company’s biologics-based investigational therapies utilize its proprietary mesenchymal stem cell secretome (MSC-S) platform. The Company’s product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biocfactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing, which is an underlying etiology of multiple severe ocular diseases; KPI-014 specific for inherited retinal degenerative diseases. KPI-012 is in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing. The Company is also engaged in the development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases.

Webull offers KALA BIO Inc stock information, including NASDAQ: KALA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KALA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KALA stock methods without spending real money on the virtual paper trading platform.